Managing Lupus Nephritis in Children and Adolescents

Paediatr Drugs. 2024 Mar;26(2):145-161. doi: 10.1007/s40272-023-00609-3. Epub 2023 Dec 20.

Abstract

Lupus nephritis is an important manifestation of systemic lupus erythematosus, which leads to chronic kidney disease, kidney failure, and can result in mortality. About 35%-60% of children with systemic lupus erythematosus develop kidney involvement. Over the past few decades, the outcome of patients with lupus nephritis has improved significantly with advances in immunosuppressive therapies and clinical management. Nonetheless, there is a paucity of high-level evidence to guide the management of childhood-onset lupus nephritis, because of the relatively small number of patients at each centre and also because children and adolescents are often excluded from clinical trials. Children and adults differ in more ways than just size, and there are remarkable differences between childhood- and adult-onset lupus nephritis in terms of disease severity, treatment efficacy, tolerance to medications and most importantly, psychosocial perspective. In this article, we review the 'art and science' of managing childhood-onset lupus nephritis, which has evolved in recent years, and highlight special considerations in this specific patient population.

Publication types

  • Review

MeSH terms

  • Adolescent
  • Adult
  • Child
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Lupus Erythematosus, Systemic* / drug therapy
  • Lupus Nephritis* / chemically induced
  • Lupus Nephritis* / drug therapy
  • Treatment Outcome

Substances

  • Immunosuppressive Agents